In particular, ROS generation and the upregulation of the main terminal UPR transcription factor, CHOP, highlighted the key role of SRs in activating the terminal UPR pathway, thus identifying pan-SR ligands as candidates for targeting the UPR in pancreatic cancer (Figure 7a,b). The gene discussed is DDIT3; the disease is familial pancreatic carcinoma.